Heron Therapeutics extends working capital loan maturity to Sept 2027 or earlier tied to convertible notes

HERON THERAPEUTICS, INC. /DE/

Extended maturity to earlier of Sept 1, 2027, or (if 1.5% convertible notes remain) May 12, 2026.
If note maturity extended beyond Aug 11, 2026, loan due 91 days prior to that extended date.
Amendment with Hercules Capital, Inc. as agent and lender, dated Feb 13, 2025.
Borrower reaffirms security grant and releases claims against lender as part of agreement.
No changes to other terms; conditions precedent include representations and no default.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.